Loperamide and P-glycoprotein inhibition: Assessment of the clinical relevance

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 4, 2010, Pages 401-412

  Vandenbossche, Joris ^a   Huisman, Maarten ^a   Xu, Yimei ^b   Sanderson Bongiovanni, Dawn ^b   Soons, Paul ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b Johnson and Johnson Pharmaceutical Services   (United States)

Author keywords

CNS depression; Inhibition; Loperamide; Opioid toxicity; P glycoprotein

Indexed keywords

CYCLOSPORIN A; DOMPERIDONE; GEMFIBROZIL; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; HM 30181A; ITRACONAZOLE; KETOCONAZOLE; LOPERAMIDE; PLACEBO; PROTEINASE INHIBITOR; QUINIDINE; RITONAVIR; SAQUINAVIR; SIMETHICONE; TARIQUIDAR; TIPRANAVIR; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ADD ON THERAPY; ALERTNESS; ANALGESIA; ANEMIA; BLOATING; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG METABOLISM; DRUG OVERDOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TRANSPORT; DRUG WITHDRAWAL; DYSPNEA; ELECTROENCEPHALOGRAPHY; FLATULENCE; GASTROENTERITIS; HUMAN; INTESTINE INFECTION; MIOSIS; MUSCLE HYPERTONIA; MUSCLE HYPOTONIA; NEUROTOXICITY; NONHUMAN; POSTMARKETING SURVEILLANCE; PROTEIN EXPRESSION; PUPIL; RECOMMENDED DRUG DOSE; RESPIRATION DEPRESSION; REVIEW; SALMONELLOSIS; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE;

ANALGESICS, OPIOID; CENTRAL NERVOUS SYSTEM; DRUG INTERACTIONS; HUMANS; LOPERAMIDE; P-GLYCOPROTEIN;

EID: 77952805625     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.62.04.0001     Document Type: Review

References (65)

1. Rapaka RS. ed. Membranes and Barriers: Targeted Drug Delivery. Proceedings from a technical review meeting. September 28-29, 1993
2. NIDA Res Monogr 1995 154 : 1 244.
3. Schinkel AH. P-Glycoprotein, a gatekeeper in the blood-brain barrier Adv Drug Deliv Rev 1999 36 : 179 194.
4. Pauli-Magnus C, Kroetz DL. Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1) Pharm Res 2004 21 : 904 913.
5. Dey S et al. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein Proc Natl Acad Sci USA 1997 94 : 10594 10599.
6. Shapiro AB, Ling V The mechanism of ATP-dependent multidrug transport by P-glycoprotein Acta Physiol Scand 1998 643 227 234.
7. Gottesman MM, Pastan I Biochemistry of multidrug resistance mediated by the multidrug transporter Annu Rev Biochem 62 : 385 427.
8. Kim RB et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein Pharm Res 1999 16 : 408 414.
9. Wacher VJ et al. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy Mol Carcinog 1995 13 : 129 134.
10. Awouters F et al. Loperamide. Survey of studies on mechanism of its antidiarrheal activity Dig Dis Sci 1993 38 : 977 995.
11. DeHaven-Hudkins DL et al. Antipruritic and antihyperalgesic actions of loperamide and analogs Life Sci 2002 71 : 2787 2796.
12. Electronic Medicines Compendium (eMC). Imodium Capsules (loperamide hydrochloride). Summary of Product Characteristics [online]. http://emc.medicines.org.uk/medicine/17605/SPC/Imodium+Capsules/ (accessed 7 December 2009)
13. Electronic Medicines Compendium (eMC). Imodium Plus Caplets (loperamide hydrochloride/simethicone). Summary of Product Characteristics [online]. http://emc.medicines.org.uk/medicine/20010/SPC/Imodium+Plus+Caplets+(P)/ (accessed 7 December 2009)
14. Lavrijsen K et al. Reduction of the prodrug loperamide oxide to its active drug loperamide in the gut of rats, dogs, and humans Drug Metab Dispos 1995 23 : 354 362.
15. Electronic Medicines Compendium (eMC). Infacol (simethicone). Summary of Product Characteristics [online]. http://emc.medicines.org.uk/medicine/1596/SPC/ Infacol/ (accessed 7 December 2009)
16. Heykants J et al. Loperamide (R 18 553), a novel type of antidiarrheal agent. Part 5: the pharmacokinetics of loperamide in rats and man Arzneimittelforschung 1974 24 : 1649 1653.
17. Heel RC et al. Loperamide: a review of its pharmacological properties and therapeutic efficacy in diarrhoea Drugs 1978 15 : 33 52.
18. Kim KA et al. Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes Eur J Clin Pharmacol 2004 60 : 575 581.
19. Lavrijsen K et al. The reduction of the prodrug loperamide oxide to its active drug loperamide, and the absorption, distribution, metabolism and excretion of loperamide oxide and loperamide in experimental animals. A review of the available data up to June 1992. Non-clinical Pharmacokinetics Report on R58425 FK-1336, June 1992. Beerse, Belgium: Johnson & Johnson Pharmaceutical Research and Development, 1992 Data on file)
20. Schinkel AH et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs J Clin Invest 1996 97 : 2517 2524.
21. 11C-loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux J Nucl Med 2008 49 : 649 656.
22. Niemegeers CJ et al. Dissociation between opiate-like and antidiarrheal activities of antidiarrheal drugs J Pharmacol Exp Ther 1979 210 : 327 333.
23. Fletcher P et al. Benefit/risk considerations with respect to OTC-descheduling of loperamide Arzneimittelforschung 1995 45 : 608 613.
24. Litovitz T et al. Surveillance of loperamide ingestions: an analysis of 216 poison center reports J Toxicol Clin Toxicol 1997 35 : 11 19.
25. Li ST et al. Loperamide therapy for acute diarrhea in children: systematic review and meta-analysis PLoS Med 2007 4 : e98.
26. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Draft Guidance for Industry. Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling. September 2006 online http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf (accessed 16 July 2008 on former URL : http://www.fda.gov/cder/Guidance/6695dft.htm)
27. Sadeque AJM et al. Increased drug delivery to the brain by P-glycoprotein inhibition Clin Pharmacol Ther 2000 68 : 231 237.
28. Phimmasone S, Kharasch ED. A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans Clin Pharmacol Ther 2001 70 : 505 517.
29. Denman WT et al. Miotic effects of alfentanil and fentanyl occur at very low doses [abstract] Anesthesiology 1997 87 : A316.
30. Kurnik D et al. Tariquidar, a selective P-glycoprotein inhibitor, does not potentiate loperamide's opioid brain effects in humans despite full inhibition of lymphocyte P-glycoprotein Anesthesiology 2008 109 : 1092 1099.
31. Pal D, Mitra AK. CYP3A4 and MDR mediated interactions in drug therapy Clin Res Reg Aff 2006 23 : 125 163.
32. Bohets H et al. Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions Br J Pharmacol 2000 129 : 1655 1667.
33. Fullerton T et al. Characterization of P-glycoprotein inhibition at the blood brain barrier by ketoconazole and quinidine [abstract] Clin Pharmacol Ther 2005 77 2 P31.
34. 11C]Loperamide in humans [abstract] NeuroImage 2008 41 2 T192.
35. Skarke C et al. Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers Pharmacogenetics 2003 13 : 651 660.
36. Hoffmeyer S et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci USA 2000 28; 97 : 3473 3478.
37. Tanabe M et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene J Pharmacol Exp Ther 2001 297 : 1137 1143.
38. Niemi M et al. Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide Eur J Clin Pharmacol 2006 62 : 463 472.
39. Jalava KM et al. Itraconazole decreases renal clearance of digoxin Ther Drug Monit 1997 19 : 609 613.
40. Ogilvie BW et al. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions Drug Metab Dispos 2006 34 : 191 197.
41. Ehrhardt M et al. Influence of lipid lowering fibrates on P-glycoprotein activity in vitro Biochem Pharmacol 2004 67 : 285 292.
42. Kivistö KT et al. Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice Naunyn Schmiedebergs Arch Pharmacol 2004 370 : 124 130.
43. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 29 January 2008 1 128 online http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed 6 August 2008)
44. Norvir (ritonavir). Annex I - Summary of Product Characteristics [online]. http://www.emea.europa.eu/humandocs/PDFs/EPAR/Norvir/H-127-PI-en.pdf (accessed 6 August 2008)
45. Aptivus (tipranavir). Annex I - Summary of Product Characteristics [online]. http://www.emea.europa.eu/humandocs/PDFs/EPAR/aptivus/H-631-PI-en.pdf (accessed 6 August 2008)
46. Invirase (saquinavir). Annex I - Summary of Product Characteristics [online]. http://www.emea.europa.eu/humandocs/PDFs/EPAR/Invirase/H-113-PI-en.pdf (accessed 6 August 2008)
47. Tayrouz Y et al. Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement Clin Pharmacol Ther 2001 70 : 405 414.
48. Mukwaya G et al. Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers Antimicrob Agents Chemother 2005 49 : 4903 4910.
49. Mikus G et al. Reduction of saquinavir exposure by coadministration of loperamide: a two-way pharmacokinetic interaction Clin Pharmacokinet 2004 43 : 1015 1024.
50. Stewart A et al. Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration Clin Cancer Res 2000 6 : 4186 4191.
51. Kim T et al. HM30181A, a novel P-glycoprotein inhibitor, increases loperamide bioavailability in healthy volunteers [abstract] Clin Pharmacol Ther 2009 85 1 S27.
52. Zhou SF, Lai X An update on clinical drug interactions with the herbal antidepressant St. John's wort Curr Drug Metab 2008 9 : 394 409.
53. Boyd RA et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion J Clin Pharmacol 2000 40 : 91 98.
54. Tornio A et al. Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8 Basic Clin Pharmacol Toxicol 2005 97 : 104 108.
55. Sakaeda T et al. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport Pharm Res 2006 23 : 506 512.
56. Kerr F et al. Quinidine overdose. Neurological and cardiovascular toxicity in a normal person Br Heart J 1971 33 : 629 631.
57. Misquitta P, Hua M. Loperamide estimated post-marketing exposure.
58. 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576 Clin Cancer Res 2003 9 : 650 656.
59. Choo EF et al. Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier J Pharmacol Exp Ther 2006 317 : 1012 1018.
60. Acharya P et al. Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells Drug Metab Dispos 2008 36 : 452 460.
61. Steemans K, Huisman M. Study on ABCB1, Abcg2 and ABCC2 mediated transport of loperamide in LLC-PK1 (ABCB1) and MDCKII (Abcg2, ABCC2) cell lines transduced with these transporters.
62. Borst P, Elferink RO. Mammalian ABC transporters in health and disease Annu Rev Biochem 2002 71 : 537 592.
63. Verstuyft C et al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms Eur. J Clin Pharmacol 2003 58 : 809 812.
64. Pauli-Magnus C et al. No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects Clin Pharmacol Ther 2003 74 : 487 498.
65. Khawaja IS et al. Herbal medicines as a factor in delirium Psychiatr Serv 1999 50 : 969 970.